EGFR Inhibitor Therapy for TRPV3-Linked Keratoderma Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for keratoderma, such as Olmsted syndrome, provide only temporary symptomatic relief and are unable to address the debilitating and progressive nature of the disease, which can lead to auto-amputation of digits and severe pain, with existing treatments failing to target the underlying cause.
Innovation Solution
Administering a therapeutically effective amount of an EGFR inhibitor, such as erlotinib, to disrupt the EGFR signaling pathway, which is implicated in the progression of keratoderma, particularly in cases associated with TRPV3 mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (emollients, keratolytics, retinoids, or corticosteroids) are used, then symptomatic relief is provided, but the treatment effect is only temporary and partial
Solution Approach 1:
The patent applies preliminary action by targeting the upstream EGFR signaling pathway before hyperkeratosis fully develops. By using EGFR inhibitors to block the activated EGFR pathway early in the disease process, the treatment prevents the progression to severe hyperkeratosis rather than merely treating established symptoms, thereby achieving more durable therapeutic effects.
Solution Approach 2:
The patent extracts and targets the specific pathological mechanism (EGFR pathway activation) from the complex disease process. By isolating and inhibiting the EGFR signaling pathway that is abnormally activated in TRPV3-mutant keratodermas, the treatment addresses the root cause rather than providing broad symptomatic relief, leading to more sustained improvement.
2Object-affected harmful factors
If current symptomatic treatments are used, then temporary relief is achieved, but the underlying cause of the disease is not addressed
Solution Approach 1:
The patent applies preliminary action by targeting the upstream EGFR signaling pathway before hyperkeratosis fully develops. By using EGFR inhibitors to block the activated EGFR pathway early in the disease process, the treatment prevents the progression to severe hyperkeratosis rather than merely treating established symptoms, thereby achieving more durable therapeutic effects.
Solution Approach 2:
The patent extracts and targets the specific pathological mechanism (EGFR pathway activation) from the complex disease process. By isolating and inhibiting the EGFR signaling pathway that is abnormally activated in TRPV3-mutant keratodermas, the treatment addresses the root cause rather than providing broad symptomatic relief, leading to more sustained improvement.
Data Source
AI summary
Olmsted syndrome (OS) is a rare genodermatosis classically characterized by the combination of bilateral mutilating transgredient palmoplantar keratoderma (PPK) and periorificial keratotic plaques. The inventors obtained remarkable results with a treatment with a EGFR inhibitor (e.g. erlotinib) in 3 patients with Olmsted Syndrome and erythemalgia linked to different TRPV3 mutations. In less than 3 months, the drug induced a complete disappearance of the hyperkeratosis and the pain. Anorexia and insomnia disappeared with an improvement of the growth. Accordingly, the present invention relates to the use of EGFR inhibitors for the keratodermas.